July 2025 News Letter

Accurate medical device classification is the starting point for every UK regulatory journey — but post-Brexit, the rules are no longer identical to those of the EU. The UK MDR 2002 (as amended) remains the UK’s primary framework, and with further MHRA reforms planned for 2025, correct classification is more important than ever.

Ask any medical-device founder what keeps them up at night, and you’ll hear the same answer: documentation.

ISO 13485 demands proof; proof that every process is defined, controlled, and recorded. Without the proper paperwork, you don’t just risk a poor audit; you risk losing months of progress and thousands in corrective rework.

Few areas of the EU Medical Device Regulation (MDR 2017/745) cause as much anxiety as clinical evaluation. Once a tick-box dossier exercise under the old MDD, it is now a continuous, evidence-driven process scrutinised by Notified Bodies and regulators alike.
As the European MDR and the US FDA’s new Quality Management System Regulation (QMSR) converge, scrutiny has intensified. Every audit now tests whether a company’s medical-device quality management system (QMS) truly works or merely exists on paper.

Risk and quality are two sides of the same compliance coin. Yet in many medical-device companies, they still live in separate silos – quality managers guard procedures while engineers manage risk files in isolation. That gap can be costly. It’s where design failures hide, where corrective actions repeat, and where auditors find the most painful non-conformities.
As the European MDR and the US FDA’s new Quality Management System Regulation (QMSR) converge, scrutiny has intensified. Every audit now tests whether a company’s medical-device quality management system (QMS) truly works or merely exists on paper.